Age at HPV vaccine initiation and completion among US adolescent girls

Trend from 2008 to 2012

Mahbubur Rahman, Christine J. McGrath, Jacqueline Hirth, Abbey Berenson

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: To examine the trend of provider-verified HPV vaccine initiation (≥1 dose) and completion (≥3 doses) among adolescent girls at the Advisory Committee on Immunization Practices (ACIP) recommended age (11-12 years). Methods: We analyzed National Immunization Survey of Teens 2008-2012 data and examined the trend of provider-verified HPV vaccine initiation and completion among <13 year old girls. Results: Data on age at HPV vaccine initiation and completion were available for 24,466 and 15,972 girls, respectively. The weighted proportion of girls who initiated the vaccine at <13 years of age was 14.1%, 24.1%, 35.9%, 47.7% and 55.9% in 2008, 2009, 2010, 2011 and 2012, respectively (p for trend <.001). The similar trend was also observed for mean age at HPV vaccine initiation and completion (p<. .001). Conclusions: Additional efforts are needed to increase HPV vaccine uptake among adolescent girls as only half of them receive this vaccine at ACIP recommended age.

Original languageEnglish (US)
Pages (from-to)585-587
Number of pages3
JournalVaccine
Volume33
Issue number5
DOIs
StatePublished - Jan 29 2015

Fingerprint

Papillomavirus Vaccines
vaccines
Immunization
Advisory Committees
immunization
Vaccines
committees
dosage
uptake mechanisms

Keywords

  • Adolescent girls
  • Age at vaccine completion
  • Age at vaccine initiation
  • HPV vaccine
  • Human papillomavirus (HPV)

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Age at HPV vaccine initiation and completion among US adolescent girls : Trend from 2008 to 2012. / Rahman, Mahbubur; McGrath, Christine J.; Hirth, Jacqueline; Berenson, Abbey.

In: Vaccine, Vol. 33, No. 5, 29.01.2015, p. 585-587.

Research output: Contribution to journalArticle

@article{efebabd68f2d4825802ca08b6afa90e0,
title = "Age at HPV vaccine initiation and completion among US adolescent girls: Trend from 2008 to 2012",
abstract = "Objective: To examine the trend of provider-verified HPV vaccine initiation (≥1 dose) and completion (≥3 doses) among adolescent girls at the Advisory Committee on Immunization Practices (ACIP) recommended age (11-12 years). Methods: We analyzed National Immunization Survey of Teens 2008-2012 data and examined the trend of provider-verified HPV vaccine initiation and completion among <13 year old girls. Results: Data on age at HPV vaccine initiation and completion were available for 24,466 and 15,972 girls, respectively. The weighted proportion of girls who initiated the vaccine at <13 years of age was 14.1{\%}, 24.1{\%}, 35.9{\%}, 47.7{\%} and 55.9{\%} in 2008, 2009, 2010, 2011 and 2012, respectively (p for trend <.001). The similar trend was also observed for mean age at HPV vaccine initiation and completion (p<. .001). Conclusions: Additional efforts are needed to increase HPV vaccine uptake among adolescent girls as only half of them receive this vaccine at ACIP recommended age.",
keywords = "Adolescent girls, Age at vaccine completion, Age at vaccine initiation, HPV vaccine, Human papillomavirus (HPV)",
author = "Mahbubur Rahman and McGrath, {Christine J.} and Jacqueline Hirth and Abbey Berenson",
year = "2015",
month = "1",
day = "29",
doi = "10.1016/j.vaccine.2014.12.021",
language = "English (US)",
volume = "33",
pages = "585--587",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Age at HPV vaccine initiation and completion among US adolescent girls

T2 - Trend from 2008 to 2012

AU - Rahman, Mahbubur

AU - McGrath, Christine J.

AU - Hirth, Jacqueline

AU - Berenson, Abbey

PY - 2015/1/29

Y1 - 2015/1/29

N2 - Objective: To examine the trend of provider-verified HPV vaccine initiation (≥1 dose) and completion (≥3 doses) among adolescent girls at the Advisory Committee on Immunization Practices (ACIP) recommended age (11-12 years). Methods: We analyzed National Immunization Survey of Teens 2008-2012 data and examined the trend of provider-verified HPV vaccine initiation and completion among <13 year old girls. Results: Data on age at HPV vaccine initiation and completion were available for 24,466 and 15,972 girls, respectively. The weighted proportion of girls who initiated the vaccine at <13 years of age was 14.1%, 24.1%, 35.9%, 47.7% and 55.9% in 2008, 2009, 2010, 2011 and 2012, respectively (p for trend <.001). The similar trend was also observed for mean age at HPV vaccine initiation and completion (p<. .001). Conclusions: Additional efforts are needed to increase HPV vaccine uptake among adolescent girls as only half of them receive this vaccine at ACIP recommended age.

AB - Objective: To examine the trend of provider-verified HPV vaccine initiation (≥1 dose) and completion (≥3 doses) among adolescent girls at the Advisory Committee on Immunization Practices (ACIP) recommended age (11-12 years). Methods: We analyzed National Immunization Survey of Teens 2008-2012 data and examined the trend of provider-verified HPV vaccine initiation and completion among <13 year old girls. Results: Data on age at HPV vaccine initiation and completion were available for 24,466 and 15,972 girls, respectively. The weighted proportion of girls who initiated the vaccine at <13 years of age was 14.1%, 24.1%, 35.9%, 47.7% and 55.9% in 2008, 2009, 2010, 2011 and 2012, respectively (p for trend <.001). The similar trend was also observed for mean age at HPV vaccine initiation and completion (p<. .001). Conclusions: Additional efforts are needed to increase HPV vaccine uptake among adolescent girls as only half of them receive this vaccine at ACIP recommended age.

KW - Adolescent girls

KW - Age at vaccine completion

KW - Age at vaccine initiation

KW - HPV vaccine

KW - Human papillomavirus (HPV)

UR - http://www.scopus.com/inward/record.url?scp=84921313515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921313515&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.12.021

DO - 10.1016/j.vaccine.2014.12.021

M3 - Article

VL - 33

SP - 585

EP - 587

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5

ER -